## Chemical Science



## CORRECTION

View Article Online
View Journal | View Issue



Cite this: Chem. Sci., 2017, 8, 5803

## Correction: Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma

M. A. Rajora, ab L. Ding, M. Valic, b W. Jiang, M. Overchuk, b J. Chen and G. Zheng habc

DOI: 10.1039/c7sc90047c

www.rsc.org/chemicalscience

Correction for 'Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma' by M. A. Rajora *et al.*, *Chem. Sci.*, 2017, DOI: 10.1039/c7sc00732a.

In Fig. 6 of the paper, the labels for the final two sets of treatment groups should be switched around as indicated in the revised figure.




Fig. 6 In vitro evaluation of pyE-LN PDT sensitization. Cell viability was normalized to untreated cells and is presented as the average of three replicates  $\pm$  standard deviation. Cells were treated with py-LN-CO (3  $\mu$ M), laser (671 nm) or a combination of laser and particle. Significant differences (\*p < 0.01, n = 3) were observed between treated and untreated cells, wherein significantly higher toxicity (\*\*p < 0.01, n = 3) was observed in U87 cells *versus* IdIA7 cells treated with particle and laser.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>&</sup>quot;Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, Ontario M5G 1L7, Canada. E-mail: gzheng@uhnresearch.ca

<sup>&</sup>lt;sup>b</sup>Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, Ontario M5S 3G9, Canada

Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada